Why are GLP-1 medications contraindicated with medullary thyroid carcinoma?

GLP-1 medications carry a black box warning for thyroid C-cell tumors based on rodent studies showing increased incidence of medullary thyroid carcinoma (MTC) at clinically relevant exposures. While no increased thyroid cancer risk has been observed in human clinical trials or post-marketing surveillance, the FDA requires this warning due to the animal data. The contraindication applies to patients with a personal or family history of MTC or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN2), which predisposes to MTC. For patients with other thyroid conditions (hypothyroidism, Hashimoto's, Graves' disease, thyroid nodules, or differentiated thyroid cancer), GLP-1 medications are generally considered safe. Routine thyroid monitoring isn't required, but patients should report symptoms of thyroid tumors: neck mass, persistent hoarseness, difficulty swallowing, or shortness of breath. The absolute risk in humans appears extremely low based on available data.